Open Access
Access granted
Subscription or Fee Access
No 3S (2016)
- Year: 2016
- Articles: 31
- URL: https://journals.eco-vector.com/2073-4034/issue/view/7033
Articles
OT REDAKTsII
Pharmateca. 2016;(3S):3-3
3-3
Uchenye obnaruzhili novye triggery razvitiya autoimmunnykh zabolevaniy
Pharmateca. 2016;(3S):4-4
4-4
FDA zaregistrirovalo novoe lekarstvennoe sredstvo dlya profilaktiki retsidivov infektsiy, vyzvannykh Clostridium difficile
Pharmateca. 2016;(3S):4a-4a
4a-4a
Nordimet (Nordimet) - novoe lekarstvennoe sredstvo dlya lecheniya revmatoidnogo artrita kompanii Nordic Group B.V
Pharmateca. 2016;(3S):4b-4b
4b-4b
Ingibitor yanus-kinaz Kselyanz (tofatsitinib) dlya lecheniya revmatoidnogo artrita
Pharmateca. 2016;(3S):4c-4c
4c-4c
Uchenye obnaruzhili vzaimosvyaz' mezhdu narusheniyami mikrobioma kishechnika i rasseyannym sklerozom
Pharmateca. 2016;(3S):5-5
5-5
Sozdan biomaterial dlya BD-pechati khryashchevoy tkani
Pharmateca. 2016;(3S):5a-5a
5a-5a
Khirurgi razrabotali innovatsionnuyu tekhnologiyu dlya vosstanovleniya grudi posle mastektomii
Pharmateca. 2016;(3S):5b-5b
5b-5b
Poyavilos' novoe vysokoeffektivnoe sredstvo protiv bolevogo sindroma pri osteoartrite
Pharmateca. 2016;(3S):5c-5c
5c-5c
Transplantatsiya stvolovykh kletok pomogaet predotvrashchat' vozrastnoy osteoporoz
Pharmateca. 2016;(3S):5-6
5-6
Evropeyskoe meditsinskoe agentstvo EMA uzhestochila pravila provedeniya klinicheskikh issledovaniya s uchastiem cheloveka
Pharmateca. 2016;(3S):6-6
6-6
Iskusstvennye pozvonki iz polimernogo materiala effektivny pri opukholyakh pozvonochnika
Pharmateca. 2016;(3S):6a-6a
6a-6a
Preparat Prolia prodemonstriroval effektivnost' v lechenii glyukokortikoidnogo osteoporoza
Pharmateca. 2016;(3S):6-7
6-7
Priem nizkikh doz aspirina v dopolnenie k osnovnym metodam lecheniya snizhaet smertnost' i progressirovanie zlokachestvennykh novoobrazovaniy na 20%
Pharmateca. 2016;(3S):7-7
7-7
Samovosstanovlenie kostnoy tkani stalo vozmozhnym
Pharmateca. 2016;(3S):7a-7a
7a-7a
Novoe vysokoeffektivnoe lekarstvennoe sredstvo dlya lecheniya revmatoidnogo artrita: dannye randomizirovannogo dvoynogo slepogo platsebo-kontroliruemogo issledovaniya
Pharmateca. 2016;(3S):7-8
7-8
Ozhirenie privodit k snizheniyu effektivnosti terapii ingibitorami faktora nekroza opukholey u bol'nykh psoriaticheskim artritom
Pharmateca. 2016;(3S):8-8
8-8
Lesinurad v sochetanii s allopurinolom dlya lecheniya patsientov s podagroy s neadekvatnym otvetom na provedennuyu ranee terapiyu
Pharmateca. 2016;(3S):8a-8a
8a-8a
Meta-analiz randomizirovannykh klinicheskikh issledovaniy ne vyyavil zavisimosti v skorosti i chastote razvitiya ranevoy infektsii pri ispol'zovanii steril'nykh perchatok po sravneniyu s nesteril'nymi dlya obrabotki ran
Pharmateca. 2016;(3S):8b-8b
8b-8b
Tofacitinib povyshaet risk razvitiya opoyasyvayushchego i prostogo gerpesa u patsientov s revmatoidnym artritom
Pharmateca. 2016;(3S):8-9
8-9
Allopurinol snizhaet risk razvitiya fibrillyatsii predserdiy u pozhilykh lyudey: issledovanie s ispol'zovaniem dannykh Medicare
Pharmateca. 2016;(3S):9-9
9-9
Epigallokatekhin-3-gallat, soderzhashchiysya v zelenom chae, predotvrashchaet razvitie vospaleniya pri revmatoidnom artrite
Pharmateca. 2016;(3S):9a-9a
9a-9a
Uchenye iz Sibirskogo federal'nogo universiteta sozdali iskusstvennye kosti
Pharmateca. 2016;(3S):9b-9b
9b-9b
RECOMMENDATIONS FOR USE OF THE RUSSIAN MODEL FRAX® FOR DETERMINING 10-YEAR PROBABILITY OF OSTEOPOROTIC FRACTURES
Abstract
The article is devoted to justification of creation, calculation methodology and interpretation of results of FRAX® algorithm to determine the 10-year probability of osteoporotic fractures. Age-related therapeutic intervention thresholds for the Russian population are presented, and coefficients of recalculation for patients receiving glucocorticoid treatment, depending on their dose, are given.
Pharmateca. 2016;(3S):10-15
10-15
CALCIUM METABOLISM AND BONE HOMEOSTASIS
Abstract
The article is devoted to a relevant topic - the relationship of calcium and bone metabolism under normal and pathological conditions. The complexity and correlation of these processes is shown. The cellular and molecular characteristics of calcium metabolism in the serum and bone tissue are discussed in detail. The article presents the modern views on the primary, secondary and contributing factors influencing the calcium metabolism. Physiological role of calcium in the human body in general and particularly in bone metabolism is clarified. The characteristic features of bone metabolism from the perspective of of cell pool, morphological types of bone tissue and their functional consistency are considered. The clinical significance of hypercalcemia is emphasized in view of the emergence of new cancer markers and subclinical inflammation markers. The role of calcium supplements in the treatment of osteoporosis from the standpoint of evidence-based medicine recommendations is discussed.
Pharmateca. 2016;(3S):16-21
16-21
CURRENT APPROACHES TO THERAPY OF PAIN SYNDROME IN SOFT TISSUE INJURIES
Abstract
This article provides information about the principles of the treatment of soft tissue injuries. Traumeel S offers an alternative approach to the treatment of inflammation and pain - the main symptoms of soft tissue injuries. It has been recently proven that the topical application of Traumeel S relieves pain and improves function in acute sprained ankle no worse than diclofenac. A group of international experts developed special treatment algorithm for the use of Traumeel S in clinical practice.
Pharmateca. 2016;(3S):22-29
22-29
HEEL PREPARATIONS IN THE COMPLEX THERAPY OF OSTEOARTHROSIS
Abstract
Despite the fact that there are many drugs with different mechanisms of action for the pain relief in osteoarthritis, none of them have an absolute efficiency. Along with well-known traditional methods of treatment of OA, which are usually used in accordance with national clinical guidelines and protocols of management of patients, there are alternative methods. Phytotherapy is one of such methods, which is widely used in various joint diseases. Currently, the multicomponent drugs known as Zeel T and Traumeel S, are manufactured for practical application in different forms.
Pharmateca. 2016;(3S):30-34
30-34
RATIONALE FOR USE OF ALFACALCIDOL IN COMBINATION WITH BISPHOSPHONATES IN POSTMENOPAUSAL AND SENILE FORMS OF SYSTEMIC OSTEOPOROSIS
Abstract
Assessment of the dynamics of bone mineral density (BMD) and parameters of calcium homeostasis in 163 patients with postmenopausal and senile forms of systemic osteoporosis treated with alfacalcidol in combination with bisphosphonates (112 patients received zoledronic acid, 51 - ibandronic acid) and calcium carbonate (1000-1200 mg/day), for 1 year confirmed that alfacalcidol, being a synthetic analogue of D-hormone, has a positive impact at personalized doses on most of the processes, which are negatively changed using bisphosphonates. In particular, the preservation of normal parameters of calcium homeostasis is a guarantee of BMD increase in this case.
Pharmateca. 2016;(3S):35-40
35-40
REGISTER OF PATIENTS WITH SYSTEMIC ANCA-ASSOCIATED VASCULITIDES AS INNOVATIVE TOOL OF PERSONALIZED THERAPY
Abstract
Anti-neutrophil cytoplasmic antibody-associated systemic vasculitides (ANCA-SV) are characterized by multiple organ lesions, clinical and immunological heterogeneity of types, a variety of manifestations, and at all stages of disease require a quality interaction between patient and doctor. The basis for successful therapy is a rational and personalized maintenance of delicate balance between the use of evidence-based treatment protocol sufficient to suppress the persistent activity of ANCA-SV, and, at the same time, control the risk of treatment complications. In response to the growing need for improved approaches to the management of patients with ANCA-SV, specialists at the FSBEI SRIR n.a. V.A. Nasonova have developed a National register of patients with ANCA-SV, which is regularly updated electronic database of dynamic monitoring of patients; it should be considered as an innovative tool for personalized induction and maintenance therapy, corresponding to the modern "treat to target“ concept. The main task of register is a stable reproduction of ANCA-SV treatment goals, including maintaining stable remission, reducing the risk of adverse effects of treatment, control of comorbid disease, and achievement of high quality of life. Further development of the National Register of ANCA-SV patients as the federal program can play a key role in improving the treatment of patients with rare and serious diseases, contribute to the development of informational and telecommunicational medical technologies to provide opportunities for emergency counseling and medical assistance in expert centers to patients with ANCA-SV, succession at different stages of treatment, reduction of pharmaco-economic costs.
Pharmateca. 2016;(3S):41-49
41-49
FOREARM BONE MINERAL DENSITY AS A PREDICTOR OF AXIAL OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH PRIOR LOW-ENERGY BONE FRACTURES
Abstract
The study was aimed to the evaluation of the possibility of using peripheral X-ray densitometry of distal forearm to predict the axial osteoporosis in postmenopausal women with prior low-energy fractures of major osteoporotic sites. The study included 134 postmenopausal women (mean age - 64.5±8.7 years) with prior low-energy fractures of the 5 locations (thigh, forearm, humeral neck, spine and ankle), who underwent densitometry of the lumbar spine and proximal femur and densitometry of distal forearm. Correlation coefficients between bone mineral density of distal forearm and proximal femur in general, femoral neck and lumbar spine were 0.58, 0.62 and 0.47, respectively. Based on ROC-curves and determination of sensitivity and specificity for different cut points, optimal values of T-score of the distal forearm were selected, allowing to predict osteoporosis in the lumbar spine, femoral neck and proximal femur as a whole with a sensitivity of 72-75 % and a specificity of 71-76%. It was concluded that peripheral densitometry of distal forearm can be used in postmenopausal women with prior low-energy fractures to predict the axial osteoporosis if central dual-energy X-ray absorptiometry is unavailable.
Pharmateca. 2016;(3S):50-55
50-55
VNIMANIYu AVTOROV!
Pharmateca. 2016;(3S):55-55
55-55